Oral anticoagulation should be managed in the community with treatment aimed at standard therapeutic targets and increased recall intervals

Journal of Thrombosis and Haemostasis

Volumn 6, Issue 10, 2008, Pages 1645-1646

  Fitzmaurice, David A ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; WARFARIN;

BLEEDING; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COMMUNITY CARE; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG USE; EUROPE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; MEDICAL DECISION MAKING; NOTE; PATIENT MONITORING; PHARMACEUTICAL CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; THROMBOSIS; UNITED KINGDOM; UNITED STATES;

ANTICOAGULANTS; ATRIAL FIBRILLATION; COMMUNITY HEALTH CENTERS; DISEASE MANAGEMENT; HEMORRHAGE; HUMANS;

EID: 52449111588     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2008.03124.x     Document Type: Note

References (3)

1. Rose A, Ozanoff A, Henault L, Hylek E. Warfarin for atrial fibrillation in community-based practise. J Thromb Haemost 2008; 6: 1647-54.
2. Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D'Angelo A, Pengo V, Erba N, Moia M, Ciavarella N, Devoto G, Berrettini M, Musolesi S. Bleeding complications of oral anticoagulant treatment: An inception-cohort, prospective collaborative study (ISCOAT). Lancet 1996; 348: 423-8.
3. Mant J, Hobbs FDR, Fletcher K, Roalfe A, Fitzmaurice DA, Lip GYH, Murray ET. Warfarin versus aspirin for stroke prevention in an elderly population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): A randomized controlled trial. Lancet 2007; 370: 493-503.